LONDON, Nov. 29, 2012 /PRNewswire/ -- Lightlake
Therapeutics Inc. (LLTP) (the "Company" or "Lightlake"), an early
stage biopharmaceutical company developing modern addiction
treatments based on its expertise using opioid antagonists,
announced today that it has appointed Mr. Kevin Pollack, who has been a member of
Lightlake's Board of Directors since April
2012, as the Company's new Chief Financial Officer.
"It has been a privilege to work with Kevin since he joined our
Board and when we look to our future as a company, we believe now
is the appropriate time to appoint him as our CFO," said Dr.
Roger Crystal, Chief Executive of
Lightlake. "Kevin has demonstrated to us his expertise in both
finance and strategy while serving on our Board, and by appointing
him as our CFO we believe he will be in a better position to
utilize his talents as we strive to build a platform of
biopharmaceutical solutions to common addictions and related
disorders."
In addition to his duties at Lightlake, Mr. Pollack is also a
Managing Director at Paragon Capital, a private investment firm
focused primarily on investing in U.S.-listed companies. He also
serves as President of Short Hills Capital LLC, where he provides a
range of advisory services to investors, asset management firms,
institutions, and companies. Mr. Pollack currently sits on the
Board of Directors of MagneGas Corporation, the developer of a
technology that converts liquid waste into a hydrogen-based metal
working fuel and natural gas alternative, as well as Pressure
BioSciences, Inc., which develops, markets and sells proprietary
laboratory instrumentation and associated consumables based on
Pressure Cycling Technology.
Mr. Pollack's past experiences include working as an investment
banker at Banc of America Securities LLC, focusing on corporate
finance and on mergers and acquisitions. He started his career at
Sidley Austin LLP (formerly Brown & Wood LLP) as a securities
attorney focusing on corporate finance and on mergers and
acquisitions. He graduated magna cum laude from The Wharton
School of the University of
Pennsylvania and received a dual J.D./M.B.A. from
Vanderbilt University, where he
graduated with Beta Gamma Sigma honors.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical
company aiming to build a platform of biopharmaceutical solutions
to common addictions and related disorders. Currently, the Company
is focused on providing a safe, effective and simple treatment for
patients who are obese or overweight as a result of Binge Eating
Disorder in addition to those patients suffering from Bulimia
Nervosa. Lightlake recently acquired patents that will allow it to
widen its product pipeline to address patients with addictions to
opioid painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Contact:
Investor
Mr. Kevin Fickle
President
NUWA Group LLC
Tel: +1-925-330-8315
Email: kevin@nuwagroup.com
Company
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-203-617-8739
Email: roger.crystal@lightlaketherapeutics.com
SOURCE Lightlake Therapeutics Inc.